Literature DB >> 26181449

Stage IV intramucosal gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type.

Masahiko Ohtaka1, Tadashi Sato2, Shouji Kobayashi2, Ryouta Sueki2, Tatsuya Yamaguchi2, Tomoyoshi Uetake2, Hiroyuki Ohtsuka2, Noriaki Iwao3, Keita Kirito3, Nobuyuki Enomoto2.   

Abstract

A 45-year-old woman with no symptoms underwent upper gastrointestinal endoscopy. A discolored area was noted at the greater curvature of the gastric upper body. Endoscopic ultrasonography demonstrated thickening of the second sonographic layer indicating that the depth of invasion was confined to the mucosa. A urea breath test and anti-Helicobacter pylori antibody test were negative. A computed tomography scan showed a consolidation at the right lung. Gastric biopsy and transbronchial lung biopsy (TBLB) demonstrated a monotonous proliferation of atypical small lymphocytes. A diagnosis of gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type (MALT lymphoma) was made. The clinical stage was stage IV. A genetic analysis showed rearrangement of the joining region of the immunoglobulin heavy chain gene and identical clones in both lesions. An API2-MALT1 fusion gene was detected in the gastric lesion. After H. pylori eradication treatment, combination treatment with rituximab plus CHOP (R-CHOP) was performed; 6 months later an endoscopy revealed complete disappearance of the lesion. Multiple gastric biopsies showed no infiltrating atypical lymphocytes. Similarly, the lesion in the lung showed complete remission (CR) on CT and TBLB. This report shows that a gastric MALT lymphoma located in the mucosa and disseminated to the lung maintained CR by R-CHOP.

Entities:  

Keywords:  API2–MALT1 fusion gene; Intramucosal gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type; Lung involvement; R-CHOP; Stage IV

Year:  2013        PMID: 26181449     DOI: 10.1007/s12328-013-0374-1

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  30 in total

1.  Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.

Authors:  Markus Raderer; Stefan Wohrer; Berthold Streubel; Johannes Drach; Ulrich Jager; Karl Turetschek; Marlene Troch; Andreas Puspok; Christoph C Zielinski; Andreas Chott
Journal:  Oncology       Date:  2007-01-12       Impact factor: 2.935

2.  Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways.

Authors:  Petr Starostik; Jochen Patzner; Axel Greiner; Stephan Schwarz; Jörg Kalla; German Ott; Hans Konrad Müller-Hermelink
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

3.  EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT.

Authors:  A Ruskoné-Fourmestraux; W Fischbach; B M P Aleman; H Boot; M Q Du; F Megraud; C Montalban; M Raderer; A Savio; A Wotherspoon
Journal:  Gut       Date:  2011-02-11       Impact factor: 23.059

4.  High relapse rate in patients with MALT lymphoma warrants lifelong follow-up.

Authors:  Markus Raderer; Berthold Streubel; Stefan Woehrer; Andreas Puespoek; Ulrich Jaeger; Michael Formanek; Andreas Chott
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

5.  t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement.

Authors:  Sung-Hsin Kuo; Ann-Lii Cheng; Chung-Wu Lin; Chih-Hung Hsu; Ming-Shiang Wu; Kun-Huei Yeh; Yi-Shin Tzeng; Li-Tzong Chen
Journal:  Cancer Chemother Pharmacol       Date:  2011-04-05       Impact factor: 3.333

6.  Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue.

Authors:  A Dogan; M Du; A Koulis; M J Briskin; P G Isaacson
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

7.  The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.

Authors:  Ellen D Remstein; Ahmet Dogan; Richard R Einerson; Sarah F Paternoster; Stephanie R Fink; Mark Law; Gordon W Dewald; Paul J Kurtin
Journal:  Am J Surg Pathol       Date:  2006-12       Impact factor: 6.394

8.  Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion.

Authors:  Hiroshi Inagaki; Tsuneya Nakamura; Chunmei Li; Toshiro Sugiyama; Masahiro Asaka; Jyunichi Kodaira; Masahiro Iwano; Tsutomu Chiba; Kazuichi Okazaki; Atsunaga Kato; Ryuzo Ueda; Tadaaki Eimoto; Shiro Okamoto; Naomi Sasaki; Naomi Uemura; Taiji Akamatsu; Hideharu Miyabayashi; Yoko Kawamura; Hidemi Goto; Yasumasa Niwa; Takio Yokoi; Masao Seto; Shigeo Nakamura
Journal:  Am J Surg Pathol       Date:  2004-12       Impact factor: 6.394

9.  Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma.

Authors:  Berthold Streubel; Hongtao Ye; Ming-Qing Du; Peter G Isaacson; Andreas Chott; Markus Raderer
Journal:  Oncology       Date:  2004       Impact factor: 2.935

10.  A phase II study of bortezomib in patients with MALT lymphoma.

Authors:  Marlene Troch; Constanze Jonak; Leonhard Müllauer; Andreas Püspök; Michael Formanek; Wolfgang Hauff; Christoph C Zielinski; Andreas Chott; Markus Raderer
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.